Sagimet Biosciences Inc. (SGMT) Stock Ticker

About Sagimet Biosciences Inc.

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

SGMT stock facts

What you can see for SGMT on Tickr

Live SGMT price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SGMT report.

Rankings